Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... pan-BCR-ABL inhibitor, AP24534, in patients with drug-resistant and refractory chronic myeloid leukemia (CML) and other hematological cancers at the upcoming American Society of Hematology ...
2009 NOV 16 ... multi-targeted kinase inhibitor. The paper, "AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance," is ...
2009 NOV 23 ... (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I ...
2009 NOV 23 ... with some degree of risk reduction for each of the five histological subtypes except chronic myeloid leukemia. Risk reductions associated with high levels of vigorous activity were more pronounced ...
2009 NOV 23 ... drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also ...
2009 NOV 17 ... developed grade II-IV acute graft-versus-host disease (GVHD) and 8 developed extensive chronic GVHD. With median follow-up of 39.1 months, event free survival and overall survival ... HCT from unrelated donors between 2000 and 2007." "Thirty-five had acute myeloidleukemia, and 21 had acute lymphoid leukemia. Stem cell sources included bone marrow in ...
2009 NOV 23 ... important new results in indications such as multiple myeloma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myeloidleukemia and myelodysplastic syndromes. ...
2009 NOV 23 ... last year with a rare type of blood cancer known as Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Kareem's cancer was diagnosed in November 2008 when a blood level test ...
2009 NOV 23 ... States report. "Here we report a case in which a patient with underlying chronic myelomonocytic leukemia was diagnosed with phlegmonous gastritis on biopsy. This ... researchers concluded: "Immunohistochemical studies further revealed the occurrence of myeloid sarcoma that involved the gastrointestinal tract." Guo and colleagues ...
2009 NOV 16 ... of the BCR-ABL inhibitor imatinib revolutionized the treatment of patients with chronic myeloid leukemia (CMIL). However, resistance to imatinib has become a clinically significant issue, ...
2009 NOV 9 ... in these patients, including optic pathway gliomas, astrocytomas, brainstem gliomas, chronic myeloid leukemia, and rhabdomyosarcoma." "with neurofibromatosis type 1 show also an ...
2009 NOV 23 ... in hematopoietic cells is unknown." "PRAME mRNA expression increased with chronic myeloid leukemia (CML) disease progression and its detection in late chronic-phase CML patients before ...
2009 NOV 23 ... 'Overcoming resistance in chronic myelogenous leukemia,' have been published. "Chronic myeloid leukemia is defined by the acquired genetic mutation, t(9;22), which leads to the fusion-protein ...
2009 NOV 23 ... "Currently, limited molecular markers exist that can determine where in the spectrum of chronic myeloid leukemia (CML) progression an individual patient falls at diagnosis. Gene expression profiles can ...
2009 NOV 16 ... (IM), the first specific inhibitor of BCR-ABLI, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML." "Despite the ...
2009 NOV 9 ... imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a ...
2009 NOV 23 ... "A 51-year-old male was diagnosed with chronic phase chronic myeloid leukemia (CML) in May 2005. His Sokal score at diagnosis was 0.95 and his Euro score was 1,363 ...
